TP53 and endometrial carcinoma: In recent years, The Cancer Genome Atlas (TCGA) and subsequent studies showed that endometrial carcinoma can be subdivided into four molecular prognostic subgroups, i.e. POLE‐mutated (POLEmut, good prognosis), microsatellite‐instability/mismatch‐repair deficient (MSI/MMRd; intermediate prognosis), copy‐number‐low/no specific molecular profile (CNL/NSMP; good‐to‐intermediate prognosis) and copy‐number‐high/p53‐abnormal (CNH/p53abn; poor prognosis).3, 5